Nanotechnologies and controlled release formulations for the administration of bisphosphonates and their potential in radiation protection

Cinnamic Acid: A Low-Toxicity Natural Bidentate Ligand for Uranium Decorporation

“…29,30 Various phosphonate ligands have been synthesized, including 1hydroxy-1,1-bisphosphonate (EHBP), which is clinically used to treat bone diseases and can effectively reduce uranium in the kidney. 31 Meanwhile, the carboxylate functions of chelating agents, such as methyl carboxylated polyethylenimine (PEI-MC), may be considered a promising new strategy for the decorporation of uranium in vivo. 28 Bidentate ligands play a pivotal role as fundamental building blocks, serving either as an agent for decorporation or as the foundation for the synthesis of other molecules.…”

“…Nevertheless, weak chelating properties, hypokalemia, and respiratory acidosis due to overuse are its clear demerits . Multidentate hydroxylpyridone (HOPO) ligands, with favorable decorporation effects, have received authorization for clinical trials and are considered the most promising U­(VI) decorporation agents. , Unfortunately, they are always synthesized using complicated procedures. , The uranyl ion, a hard Lewis acid, prefers coordination with hard donor groups such as deprotonated carboxylic and phosphonic acids. , Therefore, phosphonate ligands have shown efficacy in addressing uranium internal contamination. , Various phosphonate ligands have been synthesized, including 1-hydroxy-1,1-bisphosphonate (EHBP), which is clinically used to treat bone diseases and can effectively reduce uranium in the kidney . Meanwhile, the carboxylate functions of chelating agents, such as methyl carboxylated polyethylenimine (PEI-MC), may be considered a promising new strategy for the decorporation of uranium in vivo …”